Mediar Therapeutics and Eli Lilly have entered a global licensing agreement to advance MTX-463, a WISP1-neutralizing antibody, into a Phase 2 trial for idiopathic pulmonary fibrosis (IPF).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.